Dicot Pharma
0.23 SEK
+10.05 %
Less than 1K followers
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+10.05 %
-31.97 %
-15.34 %
-15.89 %
-27.26 %
-38.88 %
+119.44 %
-48.35 %
-89.90 %
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization. The company is based in Uppsala.
Read moreMarket cap
746.55M SEK
Turnover
4.73M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20/8
2026
Interim report Q2'26
28/10
2026
Interim report Q3'26
12/2
2027
Annual report '26
All
Webcasts
Press releases
ShowingAll content types
Dicot Pharma publishes prospectus in connection with the forthcoming rights issue
Dicot Pharma presenterar på Biostock Global Forum den 21 maj
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools